diphenylamine has been researched along with Carcinoma, Anaplastic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glassmann, A; Kraus, D; Probstmeier, R; Veit, N; Winter, J | 1 |
| De Vos, J; Klein, B; Moreaux, J; Veyrune, JL | 1 |
| Goldberg, GL; Hazan, R; Horwitz, SB; Hou, JY; McDaid, HM; Rodriguez-Gabin, A; Samaraweera, L; Samaweera, L | 1 |
| GABOR, M; KULKA, F | 2 |
| Baumgartner, JE; Benezra, M; Fagin, JA; Knauf, JA; Leboeuf, R; Malaguarnera, R; Pratilas, CA; Rosen, N; Solit, D | 1 |
6 other study(ies) available for diphenylamine and Carcinoma, Anaplastic
| Article | Year |
|---|---|
Pharmacological suppression of the Ras/MAPK pathway in thyroid carcinoma cells can provoke opposite effects on cell migration and proliferation: The appearance of yin-yang effects and the need of combinatorial treatments.
Topics: Benzamides; Carcinoma; Carcinoma, Papillary; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphenylamine; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Thyroid Cancer, Papillary; Thyroid Neoplasms; Yin-Yang | 2014 |
APRIL is overexpressed in cancer: link with tumor progression.
Topics: B-Cell Activating Factor; B-Cell Activation Factor Receptor; B-Lymphocytes; Biomarkers, Tumor; Carcinoma; Cell Proliferation; Cell Survival; Diphenylamine; Disease Progression; Heparin; Humans; Lymphoma; Multiple Myeloma; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Binding; Proteoglycans; Thyroid Neoplasms; Transmembrane Activator and CAML Interactor Protein; Tumor Necrosis Factor Ligand Superfamily Member 13 | 2009 |
Exploiting MEK inhibitor-mediated activation of ERĪ± for therapeutic intervention in ER-positive ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzamides; Carcinoma; Cell Line, Tumor; Diphenylamine; Estradiol; Estrogen Receptor alpha; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Lapatinib; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
[The diphenylamine test and the evaluation of the glycoprotein level in bronchial carcinoma].
Topics: Carcinoma; Carcinoma, Bronchogenic; Diphenylamine; Glycoproteins; Humans | 1963 |
[The diphenylamine test and the evaluation of the glycoprotein leve in bronchial carcinoma].
Topics: Carcinoma; Carcinoma, Bronchogenic; Diphenylamine; Glycoproteins; Humans | 1963 |
BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzimidazoles; Carcinoma; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation, Missense; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Substrate Specificity; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2008 |